A phase 3, randomized, placebo-controlled, double-blind study of TS-172 in hyperphosphatemia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
101
oral administration of TS-172 20\~60 mg/day
oral administration of placebo
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Achievement rate of the target serum phosphorus level
Time frame: Week 8
Change from baseline in serum concentration of phosphorus
Time frame: Up to Week 8
Concentration of corrected serum calcium
Time frame: Up to Week 8
Serum Ca × P product
Time frame: Up to Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.